Is Agenus Inc. (AGEN) a Buy, Sell, or Hold?
Agenus Inc.
NASDAQ:AGEN
$5.01 USD
-$0.07 (-1.38%)
- Volume
- 4.46M
- Average Volume
- 3.68M
- Market Capitalization
- $208.63M
- P/E Ratio
- 2.90
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $8.70
- Year Low
- $2.71
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.38
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Garo H. Armen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AGEN |
| CUSIP | 00847G804 |
| CIK | 0001098972 |
| Web | https://www.agenusbio.com |
| Phone | 781 674 4400 |
| Currency | USD |
| Employees | 81 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.38 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.38 |
| Quick Ratio | 0.38 |
| Cash Ratio | 0.14 |
Sales & Book Value
| Annual Sales | $114.2M |
| Price / Sales | 1.68 |
| Cash Flow | -2.31 |
| Price / Cash Flow | -2.38 |
| Price / Book | -0.86 |
Price Target and Rating
| Average Stock Price Forecast | $7.00 |
| High Stock Price Forecast | $8.00 |
| Low Stock Price Forecast | $7.00 |
| Forecast Upside/Downside | -28.43% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.0034 |
| Trailing P/E Ratio | 2.90 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $115K |
| Net Margin | 52.16% |
| Pretax Margin | 50.45% |
| Return on Equity | -23.05% |
| Return on Assets | 34.65% |
Financials Score
| AltmanZ Score | -14.00 |
| Piotroski Score | 5.00 |
| Working Capital | -153.95M |
| Total Assets | 186.46M |
| Ebit | 119.66M |
| Market Cap | 206.91M |
| Total Liabilities | 414.44M |
Poll Results
About Agenus Inc. (NASDAQ:AGEN) Stock
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase ... II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
2026-07-14 13:01:15
Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
2026-07-14 09:16:03
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2026-07-13 15:10:22
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
Agenus shares surge as company secures up to $340M to advance colon cancer trial
2026-07-13 13:11:59
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS) colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an additional potential $255 million available through the full exercise of purchase warrants.
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
2026-07-13 10:28:42
Agenus Inc. (NASDAQ:AGEN) stock surged over 100% in intraday trading on Monday after the immuno-oncology company unveiled an $85 million private placement that could grow to $340 million if investors fully exercise accompanying warrants.
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
2026-07-13 10:02:52
Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer.
Agenus shares surge as company secures up to $340M to advance colon cancer trial
2026-07-13 08:53:00
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to...
VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy
2026-07-13 07:00:00
VivoPower PLC (NASDAQ:VIVO, FRA:51J)’s pivot toward acquiring and developing power-secured land and powered-shell data center infrastructure has earned it...
Frequently Asked Questions
-
What is the current Agenus Inc. (AGEN) stock price?
-
Agenus Inc.(NASDAQ:AGEN) stock price is $5.01 in the last trading session. During the trading session, AGEN stock reached the peak price of $8.7 while $2.71 was the lowest point it dropped to. The percentage change in AGEN stock occurred in the recent session was --1.38% while the dollar amount for the price change in AGEN stock was -$-0.07.
-
AGEN's industry and sector of operation?
-
The NASDAQ listed AGEN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AGEN?
-
Austin Charette | Senior Director, Financial Reporting and Compliance & Principal Accounting Officer
Kamel Djazouli | Head of Medical Affairs
Stefanie Perna-Nacar | Chief Communications & Government Relations Officer
Zack Armen | Vice President of Investor Relations & Corporate Development
Robin G. Taylor | Chief Commercial Officer -
How many employees does AGEN have?
-
Number of AGEN employees currently stands at 81. AGEN operates from 3 Forbes Road, Lexington, MA 02421-7305, US.
-
Link for AGEN official website?
-
Official Website of AGEN is: https://www.agenusbio.com
-
How do I contact AGEN?
-
AGEN could be contacted at phone #781 674 4400 and can also be accessed through its website. AGEN operates from 3 Forbes Road, Lexington, MA 02421-7305, US.
-
How many shares of AGEN are traded daily?
-
The average number of AGEN shares traded daily for last 3 months was 3.68M.
-
What is the market cap of AGEN currently?
-
The market value of AGEN currently stands at $208.63M with its latest stock price at $5.01